Usefulness of Mobile Electrocardiographic Devices to Reduce Urgent Healthcare Visits
Section snippets
Methods
We performed a retrospective review of our institutional electronic health records and KardiaPro database for patients who had records for about 1 year prior to purchasing a KardiaMobile device. KardiaPro is a subscription database where ECG information can be stored by patients and reviewed by providers. We then prospectively followed them for 1 year after. We only included patients who had utilized their device at least once and are subscribed to KardiaPro. Data on baseline clinical
Results
A total of 128 patients were recruited in the study. Three patients were excluded from healthcare utilization analysis as they did not utilize their KardiaMobile at least once. Table 1 summarizes the baseline characteristics of included patients. Table 2 summarizes the indication for KardiaMobile use. Most patients utilized KardiaMobile for AF monitoring, be it paroxysmal or persistent (75.8%).
Pre- and post-KardiaMobile outcomes are shown in Table 3. Importantly, exposure to the device was
Discussion
In this study, we demonstrated that a commercially available mECG device was associated with a reduction in healthcare utilization. Importantly, patients with different arrhythmia diagnoses using KardiaMobile were included in this study. This suggests that the benefit in healthcare resource optimization can be seen in a varied population. Appropriately, the most common indication for its use was for AF monitoring, the most common clinical arrhythmia.10 Given the increasing prevalence of AF,
Author Contributions
DMJ and DRF developed the concept and co-wrote the manuscript. DMJ and CG performed data collection. JJ assisted in data collection and manuscript writing. Drew Johnson: conceptualization, investigation, writing – original draft, writing - review & editing, visualization, supervision, project administration. Joey Junarta: investigation, writing – review and editing, visualization. Christopher Gerace: investigation. Daniel Frisch: Conceptualization, writing – original draft, writing – review &
Disclosures
DRF reports consulting with AliveCor and receiving demonstration devices but no financial remuneration.
Acknowledgments
The authors would like to thank David Whellan, MD, for editing and Misung Yi, PhD, and Scott W. Keith, PhD, for assistance with statistical analysis.
References (18)
- et al.
QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation
J Electrocardiol
(2015) - et al.
Smartphone ECG for evaluation of STEMI: results of the ST LEUIS pilot study
J Electrocardiol
(2015) - et al.
Surface 12 lead electrocardiogram recordings using smart phone technology
J Electrocardiol
(2015) - et al.
Temporal trends in the incidence, prevalence, and survival of patients with atrial fibrillation from 2004 to 2016
Am J Cardiol
(2017) - et al.
screening for atrial fibrillation using a mobile, single-lead electrocardiogram in Canadian primary care clinics
Can J Cardiol
(2019) - et al.
Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): study protocol for a randomised controlled trial
Contemp Clin Trials
(2020) - et al.
Ambulatory arrhythmia monitoring: choosing the right device
Circulation
(2010) - et al.
Mobile phones in cryptogenic stroke patients bringing sIngle lead ECGs for atrial fibrillation detection (MOBILE-AF): study protocol for a randomised controlled trial
Trials
(2017) - et al.
Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol
BMJ Open
(2018)
Cited by (0)
No funding was provided for this study.